Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-ND́-4-phenethylpiperazine analogs

Susan Z. Lever, Rong Xu, Kuo Hsien Fan, Emily A. Fergason-Cantrell, Terry L. Carmack, Lisa D. Watkinson, John R. Lever

Research output: Contribution to journalArticle

Abstract

Introduction: Sigma-1 (σ1) receptor radioligands are useful for basic pharmacology studies and for imaging studies in neurology, psychiatry and oncology. We derived a hybrid structure, N-1-allyl-ND́-4-phenethylpiperazine, from known ligands TPCNE and SA4503 for use as a scaffold for development of radioiodinated σ1 receptor ligands. Methods: E-and Z-N-1-(3'-iodoallyl)-ND́-4-(3",4"-dimethoxyphenethyl)-piperazine (E-1 and Z-1), N-1-allyl-ND́-4-(3',4'-dimethoxyphenethyl)-piperazine (2) and E-N-1-(3'-iodoallyl)-ND́-4-(3"-methoxy-4'D́-hydroxyphenethyl)-piperazine (3) were synthesized. Affinities for σ1 and σ2 receptors were determined. [125I]E-1 and [125I]Z-1 were prepared and evaluated in vivo in mice. [125I]E-1 was further evaluated in σ1 receptor binding assays in vitro. Results: E-1 displayed moderately high apparent affinity (15 nM) for σ1 sites and 84-fold selectivity against σ2 sites. Z-1 showed similar σ1 affinity, but only 23-fold selectivity. In contrast, 2 exhibited poor binding to both subtypes, while 3 had good affinities but poor selectivity. E-1 profiled as a probable antagonist in the phenytoin shift assay. [125I]E-1 and [125I]Z-1 were prepared in good yields and with high specific radioactivities. Log D7.4 values (2.25 and 2.27) fall within the optimal range for in vivo studies. Both radioligands selectively labeled σ1 receptors in mouse brain and peripheral organs in vivo. [125I]E-1 showed a higher level of specific binding than [125I]Z-1 and displayed good metabolic stability. Further, [125I]E-1 selectively labeled σ1 receptors in mouse brain homogenates (Kd 3.79 nM; Bmax=599 fmol/mg protein). Conclusions: [125I]E-1 is a selective σ1 receptor radioligand that exhibits properties amenable to in vitro and in vivo studies, with possible extension to single photon emission computed tomography using iodine-123.

Original languageEnglish (US)
Pages (from-to)401-414
Number of pages14
JournalNuclear Medicine and Biology
Volume39
Issue number3
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

sigma Receptors
Ligands
Brain
Phenytoin
Neurology
Single-Photon Emission-Computed Tomography
Iodine
Radioactivity
Psychiatry
Pharmacology
piperazine
In Vitro Techniques
Proteins

Keywords

  • Allylpiperazines
  • I-125
  • Sigma receptors

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-ND́-4-phenethylpiperazine analogs. / Lever, Susan Z.; Xu, Rong; Fan, Kuo Hsien; Fergason-Cantrell, Emily A.; Carmack, Terry L.; Watkinson, Lisa D.; Lever, John R.

In: Nuclear Medicine and Biology, Vol. 39, No. 3, 04.2012, p. 401-414.

Research output: Contribution to journalArticle

Lever, Susan Z. ; Xu, Rong ; Fan, Kuo Hsien ; Fergason-Cantrell, Emily A. ; Carmack, Terry L. ; Watkinson, Lisa D. ; Lever, John R. / Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-ND́-4-phenethylpiperazine analogs. In: Nuclear Medicine and Biology. 2012 ; Vol. 39, No. 3. pp. 401-414.
@article{9d2b8c51caf94863946b04d86eabe3d1,
title = "Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-ND́-4-phenethylpiperazine analogs",
abstract = "Introduction: Sigma-1 (σ1) receptor radioligands are useful for basic pharmacology studies and for imaging studies in neurology, psychiatry and oncology. We derived a hybrid structure, N-1-allyl-ND́-4-phenethylpiperazine, from known ligands TPCNE and SA4503 for use as a scaffold for development of radioiodinated σ1 receptor ligands. Methods: E-and Z-N-1-(3'-iodoallyl)-ND́-4-(3{"},4{"}-dimethoxyphenethyl)-piperazine (E-1 and Z-1), N-1-allyl-ND́-4-(3',4'-dimethoxyphenethyl)-piperazine (2) and E-N-1-(3'-iodoallyl)-ND́-4-(3{"}-methoxy-4'D́-hydroxyphenethyl)-piperazine (3) were synthesized. Affinities for σ1 and σ2 receptors were determined. [125I]E-1 and [125I]Z-1 were prepared and evaluated in vivo in mice. [125I]E-1 was further evaluated in σ1 receptor binding assays in vitro. Results: E-1 displayed moderately high apparent affinity (15 nM) for σ1 sites and 84-fold selectivity against σ2 sites. Z-1 showed similar σ1 affinity, but only 23-fold selectivity. In contrast, 2 exhibited poor binding to both subtypes, while 3 had good affinities but poor selectivity. E-1 profiled as a probable antagonist in the phenytoin shift assay. [125I]E-1 and [125I]Z-1 were prepared in good yields and with high specific radioactivities. Log D7.4 values (2.25 and 2.27) fall within the optimal range for in vivo studies. Both radioligands selectively labeled σ1 receptors in mouse brain and peripheral organs in vivo. [125I]E-1 showed a higher level of specific binding than [125I]Z-1 and displayed good metabolic stability. Further, [125I]E-1 selectively labeled σ1 receptors in mouse brain homogenates (Kd 3.79 nM; Bmax=599 fmol/mg protein). Conclusions: [125I]E-1 is a selective σ1 receptor radioligand that exhibits properties amenable to in vitro and in vivo studies, with possible extension to single photon emission computed tomography using iodine-123.",
keywords = "Allylpiperazines, I-125, Sigma receptors",
author = "Lever, {Susan Z.} and Rong Xu and Fan, {Kuo Hsien} and Fergason-Cantrell, {Emily A.} and Carmack, {Terry L.} and Watkinson, {Lisa D.} and Lever, {John R.}",
year = "2012",
month = "4",
doi = "10.1016/j.nucmedbio.2011.10.001",
language = "English (US)",
volume = "39",
pages = "401--414",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-ND́-4-phenethylpiperazine analogs

AU - Lever, Susan Z.

AU - Xu, Rong

AU - Fan, Kuo Hsien

AU - Fergason-Cantrell, Emily A.

AU - Carmack, Terry L.

AU - Watkinson, Lisa D.

AU - Lever, John R.

PY - 2012/4

Y1 - 2012/4

N2 - Introduction: Sigma-1 (σ1) receptor radioligands are useful for basic pharmacology studies and for imaging studies in neurology, psychiatry and oncology. We derived a hybrid structure, N-1-allyl-ND́-4-phenethylpiperazine, from known ligands TPCNE and SA4503 for use as a scaffold for development of radioiodinated σ1 receptor ligands. Methods: E-and Z-N-1-(3'-iodoallyl)-ND́-4-(3",4"-dimethoxyphenethyl)-piperazine (E-1 and Z-1), N-1-allyl-ND́-4-(3',4'-dimethoxyphenethyl)-piperazine (2) and E-N-1-(3'-iodoallyl)-ND́-4-(3"-methoxy-4'D́-hydroxyphenethyl)-piperazine (3) were synthesized. Affinities for σ1 and σ2 receptors were determined. [125I]E-1 and [125I]Z-1 were prepared and evaluated in vivo in mice. [125I]E-1 was further evaluated in σ1 receptor binding assays in vitro. Results: E-1 displayed moderately high apparent affinity (15 nM) for σ1 sites and 84-fold selectivity against σ2 sites. Z-1 showed similar σ1 affinity, but only 23-fold selectivity. In contrast, 2 exhibited poor binding to both subtypes, while 3 had good affinities but poor selectivity. E-1 profiled as a probable antagonist in the phenytoin shift assay. [125I]E-1 and [125I]Z-1 were prepared in good yields and with high specific radioactivities. Log D7.4 values (2.25 and 2.27) fall within the optimal range for in vivo studies. Both radioligands selectively labeled σ1 receptors in mouse brain and peripheral organs in vivo. [125I]E-1 showed a higher level of specific binding than [125I]Z-1 and displayed good metabolic stability. Further, [125I]E-1 selectively labeled σ1 receptors in mouse brain homogenates (Kd 3.79 nM; Bmax=599 fmol/mg protein). Conclusions: [125I]E-1 is a selective σ1 receptor radioligand that exhibits properties amenable to in vitro and in vivo studies, with possible extension to single photon emission computed tomography using iodine-123.

AB - Introduction: Sigma-1 (σ1) receptor radioligands are useful for basic pharmacology studies and for imaging studies in neurology, psychiatry and oncology. We derived a hybrid structure, N-1-allyl-ND́-4-phenethylpiperazine, from known ligands TPCNE and SA4503 for use as a scaffold for development of radioiodinated σ1 receptor ligands. Methods: E-and Z-N-1-(3'-iodoallyl)-ND́-4-(3",4"-dimethoxyphenethyl)-piperazine (E-1 and Z-1), N-1-allyl-ND́-4-(3',4'-dimethoxyphenethyl)-piperazine (2) and E-N-1-(3'-iodoallyl)-ND́-4-(3"-methoxy-4'D́-hydroxyphenethyl)-piperazine (3) were synthesized. Affinities for σ1 and σ2 receptors were determined. [125I]E-1 and [125I]Z-1 were prepared and evaluated in vivo in mice. [125I]E-1 was further evaluated in σ1 receptor binding assays in vitro. Results: E-1 displayed moderately high apparent affinity (15 nM) for σ1 sites and 84-fold selectivity against σ2 sites. Z-1 showed similar σ1 affinity, but only 23-fold selectivity. In contrast, 2 exhibited poor binding to both subtypes, while 3 had good affinities but poor selectivity. E-1 profiled as a probable antagonist in the phenytoin shift assay. [125I]E-1 and [125I]Z-1 were prepared in good yields and with high specific radioactivities. Log D7.4 values (2.25 and 2.27) fall within the optimal range for in vivo studies. Both radioligands selectively labeled σ1 receptors in mouse brain and peripheral organs in vivo. [125I]E-1 showed a higher level of specific binding than [125I]Z-1 and displayed good metabolic stability. Further, [125I]E-1 selectively labeled σ1 receptors in mouse brain homogenates (Kd 3.79 nM; Bmax=599 fmol/mg protein). Conclusions: [125I]E-1 is a selective σ1 receptor radioligand that exhibits properties amenable to in vitro and in vivo studies, with possible extension to single photon emission computed tomography using iodine-123.

KW - Allylpiperazines

KW - I-125

KW - Sigma receptors

UR - http://www.scopus.com/inward/record.url?scp=84858157739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858157739&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2011.10.001

DO - 10.1016/j.nucmedbio.2011.10.001

M3 - Article

C2 - 22172395

AN - SCOPUS:84858157739

VL - 39

SP - 401

EP - 414

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 3

ER -